ClinicalTrials.gg
CompletedNCT05705271Updated Jul 9, 2025

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Finerenone (Kerendia, BAY94-8862) in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Completed at 17 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.

Enrollment
8th of 25
200 · median 100
Started
2023
with 1 other
Phase 4
11 of 25
8 open now
Registered
7th of 25
by date
Lead sponsor
8 of 25
Bayer

Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 8th largest by enrollment, is one of 2 that started in 2023, is one of 11 in phase 4, and was the 7th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing finerenone in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 2 diabetes (T2D).

In people with T2D, the body does not make enough of a hormone called insulin or does not use the insulin well enough. Insulin's role is to regulate the amount of glucose (sugar) in the blood. Too much blood sugar can cause damage to the kidneys over time. Consequently, CKD can happen as one of the complications of T2D.

The study treatment finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of the mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.

Finerenone is already available in several countries for doctors to prescribe to people with CKD and T2D. In addition, it was recently approved in India with a request to specifically gather information on finerenone therapy in Indians.

The main purpose of this study is to learn how safe finerenone is in Indian people with CKD and T2D. For this, the researchers will count the number of participants who have:

  • medical problems after taking finerenone
  • abnormal high levels of potassium in the blood (called hyperkalemia).

Researcher will also count the number of participants in whom hyperkalemia:

  • leads to stop of finerenone treatment
  • requires treatment to filter wastes and water from the blood
  • leads to a hospital stay.

Doctors keep track of all medical problems that happen in studies, even if they do not think the medical problems might be related to the study treatments.

In addition, the study team will collect more data about how well finerenone works in Indian people with CKD and T2D under real world setting. Working well means that the treatment can prevent the following from happening:

  • reduced kidney function over a period of at least 4 weeks
  • death from renal problems
  • death due to conditions affecting the heart and blood circulation
  • heart attack (blocked blood flow to the heart)
  • hospital stay due to a condition which occurs when the heart does not pump blood as well as it should
  • changes of the albumin and creatinine levels in urine.

The participants will be in the study for approximately 20 months. They will take the study treatment once daily as a tablet by mouth for 18 months. In the study, 9 visits to the study site are planned.

During the study, the study team will:

  • take blood and urine samples
  • do physical examinations
  • check the participants' overall health
  • do pregnancy tests
  • examine heart health using electrocardiogram ECG
  • check vital signs.

About 30 days after the participants take their last treatment, the study doctors and their team will check worsening of reported underlying diseases:

  • damage to the blood vessels in the tissue of the retina at the back of the eye, as a result of diabetes mellitus
  • a long-term condition where the heart does not pump blood as well as it should with symptoms such as shortness of breath, tiredness and ankle swelling
  • heart attack (blocked blood flow to the heart)
  • death due to conditions affecting the heart and blood circulation or
  • hospital stay.
03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving signed signed before any study-specific procedure and willing to comply with the study-related procedures.
  • Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
  • Participants who are drug naïve for finerenone or patients who have been initiated on finerenone therapy within 4 weeks before signing the informed consent.
  • Participants with serum potassium level ≤ 4.8 mmol/L at the time of Screening. If serum potassium level > 4.8 to 5.0 mmol/L, participants may be enrolled in the study, but additional potassium samples may be required; the potassium level needs to be confirmed during Screening. Participants with potassium level > 5.0 mmol/L are not allowed. The sample for potassium assessment for confirming eligibility shall be available before initiation of treatment with finerenone.
  • use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • according to the local marketing authorization:

    1. Participants with \< 25 mL/min/1.73 m\^2 (calculated based on the CKD-EPI equation, using 2009 formula). eGFR can be reassessed once within 48 hours.
    2. Participants with severe hepatic impairment ( C).
    3. Participants with known to the study treatment (active substance or ).
    4. Participants with Type 1 Diabetes.
    5. Participants taking concomitant medications that are strong inhibitors.
    6. Participants with Addison's disease.
  • > 12% (17.5 mmol/L) at the Screening visit.
  • Participants treated with another mineralocorticoid receptor antagonist (MRA), a renin inhibitor, potassium supplements, a potassium sparing diuretic, a potassium binder agent, or angiotensin receptor neprilysin inhibitor (ARNI) within 8 weeks prior to the Screening visit and during finerenone treatment.
  • Participation in another interventional clinical trial within 30 days prior to the Screening visit and during finerenone treatment.
  • Female participants who are pregnant or breast-feeding or plan to become pregnant or to breastfeed during the course of the study.
  • Participants known for lack of compliance with clinic visits or prescribed medication.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Finerenone

    Participants will receive study treatment for 18 months ± 7 days.

    Drug: Finerenone (Kerendia, BAY94-8862)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    Time frame: From the first finerenone treatment date up to 30 days after the last treatment date

  2. Number of participants with hyperkalemia events

    including hyperkalemia (serum potassium \> 5.5 mmol/L), severe hyperkalemia (serum potassium \> 6.0 mmol/L), hyperkalemia leading to study drug discontinuation, hyperkalemia leading to dialysis and hyperkalemia leading to hospitalization

    Time frame: Up to 19 months

Secondary outcomes

  1. Time to the first occurrence of the composite of kidney failure, a sustained decrease of at least 40% in the estimated glomerular filtration Rate (eGFR) from baseline over a period of at least 4 weeks, or death from renal cause

    Time frame: Up to 19 months

  2. Time to the first occurrence of composite of cardiovascular (CV) death, nonfatal myocardial infarction, or hospitalization for heart failure (HF)

    Time frame: Up to 19 months

  3. Change in urine albumin-to-creatinine ratio (UACR) from baseline to 4 months

    Time frame: From baseline to 4 months

07

Study locations

17 sites
  • Bhate Hospital
    Karnataka, Belagavi 590002, India
  • Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)
    Nadiād, Gujarat 387001, India
  • Accord Superspeciality Hospital
    Faridabad, Haryana 121002, India
  • Kempegowda Institute of Medical Sciences Hospital & R C
    Bangalore, Karnataka 560004, India
  • Christian Medical College
    Vellore, Kerala 632004, India
  • Global Hospital-Super Speciality And Transplant Centre
    Mumbai, Maharashtra 400012, India
  • Lancelot Medical Centre
    Mumbai, Maharashtra 400092, India
  • Dr Balabhai Nanavati Hospital
    Mumbai, Maharashtra,, Maharashtra 400056, India
  • PSRI Institute of Renal Sciences
    New Delhi, National Capital Territory of Delhi 110017, India
  • Vardhman Mahavir Medical College & Safdarjung Hospital (VMMC-SJH)
    New Delhi, National Capital Territory of Delhi 110029, India
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
  • Jawaharlal Institute Of Postgraduate Medical Education and R
    Gorimedu, Puducherry 605006, India
  • Government Stanley Medical College and Hospital
    Chennai, Tamil Nadu 600001, India
  • M.V. Hospital & Research Centre 314/30
    Chowk Lucknow, Uttar Pradesh 226003, India
  • Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
    Lucknow, Uttar Pradesh 226 014, India
  • Medica Superspecialty Hospital
    Kolkata, West Bengal 700099, India
  • Nizam's Institute of Medical Sciences (NIMS)
    Hyderabad, 500082, India
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jul 2025, 28 months.

Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Jan 30, 2023
StartActual
Feb 8, 2023
Primary completionActual
Jul 3, 2025
CompletionActual
Jul 3, 2025
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05705271
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Feb 8, 2023
Primary completion
Jul 3, 2025
Completion
Jul 3, 2025
Last update
Jul 9, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion